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Background: Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for
women with early breast cancer.
Patients and methods: Patients participated in two International Breast Cancer Study Group randomized trials
testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or postmenopausal (trial IX) node-negative
breast cancer. PVI was assessed by institutional pathologists and/or central review on hematoxylin–eosin-stained
slides in 99% of patients (analysis cohort 2754 patients, median follow-up >9 years).
Results: PVI, present in 23% of the tumors, was associated with higher grade tumors and larger tumor size (trial IX
only). Presence of PVI increased locoregional and distant recurrence and was significantly associated with poorer
disease-free survival. The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with
endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of
goserelin was limited to patients whose tumors showed PVI. In trial IX, all patients received tamoxifen: the adverse
prognostic impact of PVI was limited to patients with receptor-negative tumors regardless of chemotherapy.
Conclusion: Adequate endocrine adjuvant therapy appears to abrogate the adverse impact of PVI in node-negative
disease, while PVI may identify patients who will benefit particularly from adjuvant therapy.
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introduction
Metastasis is a crucial feature of malignancy. In most cases, an
early metastatic event is the invasion of lymphatic or blood
vessels. Detection of such vascular invasion in patients with early
breast cancer has been observed by our own group [1–3] and
others [4–9] to be an adverse prognostic factor in breast cancer.
Similar findings have been reported in other cancer types [10–
13]. In patients with axillary node-negative breast cancer,
vascular invasion may be a marker of occult nodal metastasis
[14, 15] or of the risk of direct hematogenous spread.
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In the present study, we examine the prognostic significance
of peritumoral vascular invasion (PVI) in two randomized
controlled trials conducted by the International Breast Cancer
Study Group (IBCSG) in patients with node-negative breast
cancer. In particular, we find that the adverse prognostic effect
of PVI is not seen among patients assigned what is now
regarded as adequate endocrine therapy. Evaluation of
prognostic factors such as PVI, in the context of clinical trials,
has the advantage that treatment allocation is unbiased, and
follow-up and reporting are likely to be more standardized than
in non-trial series.
patients and methods
IBCSG trials VIII and IX
Patients were treated in one of two IBCSG randomized clinical trials, which
have been described in detail elsewhere [16, 17]. Briefly, from March 1990
through October 1999, IBCSG trial VIII [16] randomly assigned 1109
premenopausal or perimenopausal breast cancer patients with node-
negative disease to receive one of four treatments: (i) no adjuvant systemic
treatment; (ii) goserelin (3.6 mg s.c. implants monthly) for 24 months; (iii)
six 28-day courses of ‘classical’ cyclophosphamide, methotrexate and
5-fluorouracil (CMF) or (iv) six courses of classical CMF followed by
18-monthly doses of goserelin. Systemic adjuvant therapy was to begin
within 6 weeks of primary surgery. In April 1992, on the basis of results
from other trials, randomization to the no adjuvant treatment control arm
was discontinued after enrolling a total of 205 patients, 46 of them to the
control arm. From October 1988 to August 1999, IBCSG trial IX [17]
randomly assigned 1669 eligible and assessable postmenopausal breast
cancer patients with node-negative disease to receive one of two adjuvant
therapy regimens: tamoxifen 20 mg daily for 5 years or three cycles of
classical CMF followed by tamoxifen 20 mg daily for 57 months.
In both trials, patients with estrogen receptor (ER)-positive, ER-negative
and ER-unknown tumors (ER-unknown status allowed only if ER
determination was not possible because of lack of tumor material) were
eligible until 1998; at that time, protocol amendments restricted enrollment
to patients with ER-positive tumors. Over 94% of patients were
randomized before the amendments’ release. Institutional review boards
reviewed and approved the protocols, and informed consent was required
according to the criteria established within the individual countries.
vascular invasion
In these trials, PVI was requested as part of the routine pathological work-
up at study entry and at central pathology review of a hematoxylin and
eosin section using criteria previously described [1]. PVI was defined as the
presence of tumor cell emboli within a vessel space, which were identified
by associated fibrin clot and/or an endothelial cell lining. The study
protocol required that at least two sections of primary tumor be taken at
right angles to one another to include the interface of the growing tumor
border and the adjacent breast tissue. Generally, 6 cm2 of breast tissue
immediately adjacent to the primary tumor, but within 1 cm of the tumor
border, was available for the assessment of PVI. Routine hematoxylin and
eosin sections were used, and blood and lymphatic vessel invasion was not
distinguished.
PVI was recorded as present, absent or not done at both local and central
assessments (Table 1). For this analysis, we have defined PVI as ‘present’ if
PVI was assessed as present by either the local pathologist or the central
reviewer and ‘absent’ otherwise. The 24 cases not examined by either local
pathologist or central reviewer are not included in the analysis cohort.
classification of hormone receptor status
Presence or absence of ER and progesterone receptor (PgR) was determined
from central review [18] when available (82% of cases), with presence
defined as ‡1% immunoreactive cells. The remainder were classified based
on local assessment using immunohistochemistry when available or ligand-
binding assay results otherwise [18]. In trial VIII, tumors were considered
hormone receptor present if one or both of ER or PgR was present and were
classified as hormone receptor absent if ER was absent and PgR was either
absent or unknown. In trial IX, hormone receptor status was based on ER
only. In both trials, if the ER status of the tumor was unknown, hormone
receptor status was classified as unknown, and these 24 patients were not
included in analyses using hormone receptor status.
assessment of ‘adequate’ adjuvant therapy
Since these trials were designed, evidence has emerged that premenopausal
patients with hormone receptor-positive tumors are not adequately treated
by chemotherapy alone, as was common in the 1990s [19]. For trial VIII,
therefore, adequate treatment of patients having tumors expressing
hormone receptors was defined as treatment including the gonadotropin-
releasing hormone analogue goserelin; among patients with hormone
receptor-absent tumors, treatment with chemotherapy was considered
adequate. Similarly, in the light of our own [17] and other [20] data,
adequate therapy for patients in trial IX whose tumors did not express
hormone receptors was defined as including CMF chemotherapy.
statistical methods
The two trials were analyzed separately. The association of presence of PVI
with clinical and pathological features was assessed using Fisher’s exact tests.
Disease-free survival (DFS) was defined in the trials [16, 17] as the length of
time from the date of randomization to any relapse (including ipsilateral
breast recurrence, contralateral breast cancer and distant recurrence),
second primary malignancy, or death, whichever occurred first. The
distribution of DFS was summarized using the Kaplan–Meier method [21].
Proportional hazards regression [22] was used to investigate the
associations of PVI and other factors with DFS and estimate hazard ratios
(HRs).
In exploratory analyses of the relation of PVI and adequate adjuvant
therapy with DFS, for trial VIII the following groups were considered:
goserelin containing (goserelin or CMF/ goserelin) or not (no treatment
Table 1. PVI as reported by local pathology and by central pathology review
PVI Trial VIII (premenopausal; N = 1109) Trial IX (postmenopausal; N = 1669)
Local, n (%) Central, n (%) Overalla, n (%) Local, n (%) Central, n (%) Overalla, n (%)
Absent 875 (79) 829 (75) 832 (75) 1268 (76) 1284 (77) 1283 (77)
Present 168 (15) 180 (16) 264 (24) 244 (15) 232 (14) 375 (22)
Not examined 66 (6) 100 (9) 13 (1) 157 (9) 153 (9) 11 (1)
aThe ‘overall’ proportion is classified as ‘present’ if PVI was noted by either the local pathologist or during central pathology review.
PVI, peritumoral vascular invasion.
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or CMF) among hormone receptor-expressing tumors and CMF containing
(CMF or CMF/ goserelin) or not (goserelin or no treatment) among
hormone receptor-absent tumors.
Cumulative incidence of locoregional failure and of distant recurrence
(including contralateral breast event) was estimated in the presence of
‘other’ events (second primary cancer and death without recurrence) and
assessed using Gray’s test [23].
Median follow-up at the time of analysis was 9.8 years for trial VIII and
10.9 years for trial IX.
results
Of 2778 patients, 2754 (99%) had PVI assessment available and
represent the analysis cohort. PVI was present in 264
Table 2. Association of PVI with other clinical and pathological characteristics
Trial VIII (premenopausal) Trial IX (postmenopausal)
Vascular invasion Vascular invasion
Absent Present Absent Present
n %a n %a n %a n %a
All patients 832 264 1283 375
Age at randomization
£39 160 19.2 56 21.2 1 0.1 – –
40–49 527 63.3 166 62.9 22 1.7 13 3.5
50–59 145 17.4 42 15.9 536 41.8 163 43.5
‡60 – – – – 724 56.4 199 53.1
Local treatment
Mastectomy 355 42.7 128 48.5 629 49.0 194 51.7
BCS with RT 431 51.8 122 46.2 574 44.7 163 43.5
BCS without RT 46 5.5 14 5.3 80 6.2 18 4.8
Treatment assignment
No treatment 34 4.1 12 4.5 – – – –
Goserelin · 24 265 31.9 77 29.2
CMF · 6 258 31.0 96 36.4 – – – –
CMF · 6/ goserelin · 18 275 33.1 79 29.9 – – – –
Tamoxifen – – – – 656 51.1 185 49.3
CMF/ tamoxifen – – – – 627 48.9 190 50.7
ER status
Absent 164 19.7 48 18.2 214 16.7 76 20.3
Present 661 79.4 216 81.8 1048 81.7 297 79.2
Unknown 7 0.8 – – 21 1.6 2 0.5
PgR status
Absent 193 23.2 57 21.6 367 28.6 124 33.1
Present 623 74.9 197 74.6 867 67.6 243 64.8
Unknown 16 1.9 10 3.8 49 3.8 8 2.1
Hormone receptor status
Absent 144 17.3 46 17.4 214 16.7 76 20.3
Present 681 81.9 218 82.6 1048 81.7 297 79.2
Unknown 7 0.6 – – 21 1.6 2 0.5
Tumor sizeb
£2 cm 521 62.6 153 58.0 786 61.3 198 52.8
>2 cm 302 36.3 108 40.9 459 35.8 173 46.1
Unknown 9 1.1 3 1.1 38 3.0 4 1.1
Tumor gradec
1 162 19.5 31 11.7 257 20.0 34 9.1
2 360 43.3 122 46.2 530 41.3 164 43.7
3 297 35.7 110 41.7 415 32.3 171 45.6
Unknown 13 1.6 1 0.4 81 6.3 6 1.6
aColumn percentages.
bIn trial IX, the association of larger tumors with presence of PVI was significant: P < 0.0001.
cIn each trial, this association was significant, trial VIII: P = 0.008 and trial IX: P < 0.0001.
All other associations in Table 2 were not statistically significant (Fisher’s exact tests).
PVI, peritumoral vascular invasion; BCS, breast-conserving surgery; RT, adjuvant radiotherapy; CMF, cyclophosphamide, methotrexate and 5-fluorouracil
chemotherapy; ER, estrogen receptor; PgR, progesterone receptor (trial VIII hormone receptor status is based on ER and PgR status and in trial IX, ER status only).
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premenopausal patients’ tumors (23.8%) in trial VIII and 375
postmenopausal patients’ tumors (22.5%) in trial IX (Table 1).
associations of PVI with clinical and pathological
factors
In univariate analyses, we found an association between the
presence of PVI and higher tumor grade both in trial VIII (P =
0.008) and trial IX (P < 0.0001). Among postmenopausal
patients in trial IX, the presence of PVI was also associated with
larger tumor size (P < 0.0001). Other associations with
clinical and pathological factors were not statistically significant
(Table 2).
locoregional failure and distant recurrence
The presence of PVI significantly increased the cumulative
incidence of both locoregional failure and distant recurrence
among premenopausal patients (trial VIII; P = 0.001 and P =
0.04, respectively), where the difference in locoregional failure
became evident 1 year after randomization (Figure 1A and B).
The association between PVI and locoregional failure was not
statistically significant for postmenopausal patients (trial IX;
P = 0.08 and P = 0.18, respectively) but the patterns of
recurrence were similar to those observed among
premenopausal patients in trial VIII (Figure 1C and D).
PVI and DFS
Overall, DFS was significantly longer in patients whose tumors
did not have PVI compared with those with PVI (Figure 2A and
C). In univariate analyses, among premenopausal patients in
trial VIII, the hazard of a DFS event was increased by 61% [HR
1.61, 95% confidence interval (CI) 1.2–2.1; P < 0.001] for
patients with PVI present compared with patients without PVI.
Among postmenopausal patients in trial IX, the hazard of
a DFS event was increased by 27% in patients whose tumors
had PVI (HR 1.27, 95% CI 1.04–1.5; P = 0.02) (Table 3).
Figure 2B and D summarizes DFS according to the tumor
hormone receptor status and PVI. Among premenopausal
patients (trial VIII), there was heterogeneity in the association
of PVI with DFS according to the hormone receptor status (P =
0.04 for interaction; Table 3). The presence of PVI was
associated with an increased hazard of a DFS event for patients
with hormone receptor-present tumors (HR 1.83, 95% CI
1.38–2.43) that was not evident in patients with tumors that did
not express hormone receptors (HR 1.08, 95% CI 0.63–1.84).
DFS was longest for patients whose tumors expressed hormone
receptors and were absent of PVI (Figure 2B); DFS for the
remaining three subgroups was comparable by 7 years
following randomization. Similarly, there was heterogeneity
among postmenopausal patients (trial IX; P = 0.02 for
interaction; Table 3). However, in contrast, the presence of PVI
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Figure 1. Cumulative incidence of (A) locoregional or (B) distant recurrence in trial VIII (premenopausal) according to the presence or absence of
peritumoral vascular invasion and in trial IX [postmenopausal (C and D)].
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was associated with an increased hazard of a DFS event for
patients with hormone receptor-absent tumors (HR 1.54, 95%
CI 1.01–2.38) and not in patients with hormone receptor-
present tumors (HR 1.19, 95% CI 0.95–1.49). For trial IX, the
poorest DFS was observed in patients whose tumors were
hormone receptor absent and PVI present (Figure 2D). When
the models were adjusted for other covariates, the presence of
PVI maintained its prognostic importance.
effects of treatments and PVI on DFS
In exploratory, hypothesis-generating analyses, we investigated
the relative value of adjuvant treatments in patient cohorts
defined by hormone receptor status.
hormone receptor-expressing tumors. Figure 3A and B
summarizes DFS for premenopausal patients with hormone
receptor-present tumors according to the PVI status and
treatment in trial VIII. The plots indicate that with PVI present,
treatments including goserelin provided more favorable DFS
compared with CMF-only treatment or no treatment (Figure
3B). This observation was supported by the statistical models of
adequate therapy, which showed a significant relationship
between PVI and goserelin-containing treatment (P = 0.03 for
interaction). When PVI was present, there was an increased
hazard of a DFS event when treatment did not contain
goserelin [HR (no goserelin : goserelin) = 1.75, 95% CI
1.11–2.76], but similar benefits of all treatments when tumors
did not manifest PVI [HR (no goserelin : goserelin) = 0.94,
95% CI 0.66–1.32] (Table 4).
We further explored ‘inadequate’ therapy with CMF alone
according to age, as the results of trial VIII indicated poorer
outcome among younger premenopausal patients treated with
CMF alone for hormone receptor-expressing tumors. There
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Figure 2. Disease-free survival (DFS) according to the presence or absence of peritumoral vascular invasion (PVI) for (A) trial VIII all premenopausal
patients, (B) trial VIII according to hormone receptor status, (C) trial IX all postmenopausal patients and (D) trial IX according to hormone receptor status.
Table 3. The association of presence of PVI with DFS, among all
patients and for subgroups defined by hormone receptor status
DFS hazard ratio (95% CI) for
effect of PVI presence : absence
Trial VIII
(premenopausal)
Trial IX
(postmenopausal)
All patients 1.61 (1.20–2.10);
P = 0.0001
1.27 (1.04–1.50);
P = 0.02
Hormone receptor statusa
Present 1.83 (1.38–2.43) 1.19 (0.95–1.49)
Absent 1.08 (0.63–1.84) 1.54 (1.01–2.38)
aThere was heterogeneity in the association of PVI with DFS according to
hormone receptor status: trial VIII, P = 0.04 for interaction; trial IX, P =
0.02 for interaction.
PVI, peritumoral vascular invasion; DFS, disease-free survival; CI,
confidence interval.
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was a suggestion of a differential association of PVI with DFS
according to age (P = 0.05 for interaction); DFS was adversely
influenced by the presence of PVI with the effect upon younger
premenopausal patients more pronounced (HR 6.65, 95% CI
2.80–15.70) than upon older premenopausal patients (HR 2.29,
95% CI 1.34–4.30).
In the original trial IX results, there was no benefit of CMF
preceding tamoxifen versus tamoxifen alone among these
postmenopausal women with ER-expressing tumors; this result
was observed regardless of whether PVI was present or absent
(P = 0.67 for interaction; Table 4).
Hormone receptor-absent tumors. Somewhat parallel, though
less clear, results were seen in premenopausal patients with
receptor-absent tumors and CMF-containing treatments
(Figure 3C and D, P = 0.11 for interaction). Patients with
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receptor-absent tumors with PVI had a threefold increase
in the hazard of a DFS event when treatment did not
contain CMF [HR (no CMF : CMF) = 3.20, 95% CI 1.24–
8.26], but more similar benefits of treatments when PVI was
absent [HR (no CMF : CMF) = 1.32, 95% CI 0.77–2.26]
(Table 4).
Among the postmenopausal patients in trial IX, the benefit of
additional CMF preceding tamoxifen compared with tamoxifen
alone was seen exclusively in patients whose tumors did not
express ER. The benefit of chemotherapy was similar in cohorts
with or without PVI (Table 4, Figure 3E and F), with the hazard
of a DFS event approximately halved by treatment with CMF
followed by tamoxifen versus tamoxifen alone.
discussion
Metastasis is the dominant lethal event in breast cancer. Since
most metastasis must spread through lymphatic or blood
vessels, it is intuitively likely that the demonstration of tumor
invasion of vascular spaces should be an adverse prognostic
indicator. Such an association has been reported in several
series [1–9], though not others [24, 25]. Earlier work from the
IBCSG has shown that the presence of vascular invasion
predicts the presence of occult lymph node metastases on serial
sectioning [14] and predicts the presence of positive sentinel
nodes [15]. Thus, patients identified in these studies as node
negative by routine pathological assessment, but whose tumors
showed PVI, may in fact have harbored undetected nodal
metastases. It should follow that the conclusions of this study
may extend to patients with at least some detectable nodal
involvement.
It has been claimed that factor VIII staining can help
discriminate between blood and lymphatic vessel spaces
[26–28], though others have questioned the reliability of this
marker [29, 30]. More recently, the marker D2-40 has been
used to distinguish lymphatic from blood vessel invasion [31,
32]. Our study was based on routine review of hematoxylin–
eosin-stained slides by standard criteria [1], and no attempt was
made to discriminate between blood vessel and lymphatic vessel
invasion. Like Pinder et al. [6], we found that PVI was
associated with tumor grade and tumor size (in trial IX
postmenopausal patients only), but not with menopausal status
or hormone receptor expression.
It might be expected that vascular invasion, especially
lymphatic vessel invasion, could predict locoregional failure.
Such an association has been reported [6] among patients who
received no systemic adjuvant therapy. In our series, the
association between PVI and locoregional failure was marked in
trial VIII in which some premenopausal patients were treated
without specific endocrine adjuvant therapy, but was marginal
in trial IX, in which all postmenopausal patients received
tamoxifen.
The prognostic significance of PVI for DFS was particularly
evident among participants in the premenopausal trial VIII in
which some patients were treated without endocrine adjuvant
therapy despite the presence of hormone receptors. We have
since described a poorer prognosis among younger patients
with receptor-positive breast cancer treated only with
chemotherapy [19].
We observed a particularly strong adverse prognostic effect
of PVI among the small number of patients who were assigned
no adjuvant therapy in the earlier part of trial VIII (Figure 3B),
a finding reminiscent of the strong effect seen in the
Nottingham series [6] in which no adjuvant systemic therapy
was given. We also found an adverse prognostic effect in trial
VIII among patients with receptor-positive tumors treated only
with CMF chemotherapy, especially those aged £40 years,
perhaps reflecting the unreliable ovarian-suppressive effects of
CMF in younger premenopausal patients [16], while older
patients treated with CMF alone may have derived partial
endocrine therapeutic benefit from chemotherapy-induced
ovarian suppression.
It was also striking that the adverse prognostic effect of
omitting goserelin treatment of premenopausal patients (trial
VIII) with receptor-positive disease was confined to patients
whose tumors showed PVI (HR 1.75) and completely absent
(HR 0.94) among those whose tumors did not. In contrast,
the adverse effect of omitting CMF in hormone receptor-
negative disease was less clearly linked to PVI. In
postmenopausal patients with receptor-negative disease, the
effect of omitting CMF was similar in the presence or absence
of PVI.
Table 4. The association of adequate adjuvant therapy and PVI with DFS according to tumor hormone receptor status
DFS hazard ratio (95% CI) Interaction
PVI absent PVI present P value
Trial VIII (premenopausal)
Hormone receptor present
Inadequate (no goserelin) : adequate (goserelin) 0.94 (0.66–1.32) 1.75 (1.11–2.76) 0.03
Hormone receptor absent
Inadequate (no CMF) : adequate (CMF) 1.32 (0.77–2.26) 3.20 (1.24–8.26) 0.11
Trial IX (postmenopausal)
Hormone receptor present
CMF/ Tam : Tam 0.94 (0.75–1.19) 1.04 (0.70–1.54) 0.67
Hormone receptor absent
Adequate (CMF/ Tam) : adequate (Tam) 0.46 (0.27–0.77) 0.52 (0.25–1.06) 0.79
PVI, peritumoral vascular invasion; DFS, disease-free survival; CI, confidence interval; CMF, cyclophosphamide, methotrexate and 5-fluorouracil
chemotherapy; Tam, tamoxifen.
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The present study, although based on large prospective
randomized trials, involves retrospective subset analyses and
may reflect the play of chance. We therefore encourage clinical
trial groups with series of patients with node-negative,
endocrine-responsive disease to examine the impact of PVI. If
confirmed, the abrogation of the adverse effect of PVI by
endocrine therapy and the association between PVI and the
efficacy of endocrine therapy might indicate that endocrine
therapy has a specific role in the later stages of the metastatic
process such as implantation and angiogenesis: a role
apparently not shared by adjuvant cytotoxic therapy of overall
similar efficacy. Conversely, it is possible that PVI is a marker
for tumor cells particularly sensitive to endocrine therapy.
Our study indicates that, in premenopausal patients, the
presence of PVI in receptor-positive tumors without lymph node
metastases carries adverse prognostic significance, which can be
overcome by appropriate specific endocrine adjuvant therapy.
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